Table 2 Subject disposition
Subjects | PA safety | PA efficacy (ITT) | MQ + AS safety/efficacy | AL safety/efficacy | CQ safety | All comparators safetya |
|---|---|---|---|---|---|---|
Treatedb | 2815 | 2052 | 423 | 603 | 228 | 1254 |
Completed treatmentc | 2773 (98.5) | 2017 (98.3) | 418 (98.8) | 587 (97.3) | 220 (96.5) | 1225 (97.7) |
Completed study | 2410 (85.6) | 1748 (85.2) | 357 (84.4) | 489 (81.1) | 187 (82.0) | 1033 (82.4) |
Discontinued: | 405 (14.4) | 304 (14.8) | 66 (15.6) | 114 (18.9) | 41 (18.0) | 221 (17.6) |
 Adverse event | 46 (1.6) | 32 (1.6) | 4 (0.9) | 10 (1.7) | 2 (0.9) | 16 (1.3) |
 Consent withdrawn | 26 (0.9) | 19 (0.9) | 6 (1.4) | 11 (1.8) | 5 (2.2) | 22 (1.8) |
 Insufficient therapeutic effect | 11 (0.4) | 0 | 0 | 0 | 0 | 0 |
 Lost to follow-up | 99 (3.5) | 69 (3.4) | 25 (5.9) | 10 (1.7) | 12 (5.3) | 47 (3.7) |
 Protocol violation | 9 (0.3) | 4 (0.2) | 0 | 1 (0.2) | 0 | 1 (0.1) |
 Malaria infection | 186 (6.6) | 174 (8.5) | 29 (6.9) | 78 (12.9) | 21 (9.2) | 128 (10.2) |
 Other | 28 (1.0) | 6 (0.3) | 2 (0.5) | 4 (0.7) | 1 (0.4) | 7 (0.6) |